Palvella Therapeutics, Inc. has announced the commencement of dosing in its Phase 3 SELVA trial, aimed at evaluating QTORIN™ ...

“The simple answer is that we don’t know yet,” says Leslie Kenny, a longevity expert. What we know so far is that “rapamycin ...

Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the third ...

Celcuity's lead asset, Gedatolisib, is a dual PI3K/mTOR inhibitor targeting various cancers, currently in multiple Phase 3 ...

Kazia Therapeutics (KZIA) announced that the U.S. FDA has granted a Type C meeting with the company in December to discuss the potential pathways to registration of Kazia’s blood brain barrier ...

A new research paper titled "Initiation of tumor dormancy by the lymphovascular embolus" has been published in Oncotarget ...

A new research paper was published in Oncotarget's Volume 15 on October 11, 2024, entitled "Initiation of tumor dormancy by the lymphovascular embolus." ...

Both our experimental as well as observational studies indicate that in vivo lymphovascular tumor emboli and their in vitro spheroid equivalent ...

In an interview with Targeted Oncology, Jacob Stein, MD, MPH, discussed nab-sirolimus and its impact on patients with ...

深夜科普靠mRNA疫苗阻止肾衰？与系统性红斑狼疮相关的狼疮性肾炎靶点确认！这几天关于那个去瑞士“安乐死”的新闻比较多，但看了下除了在事件中表达立场和介绍基本的红斑狼疮（SLE）疾病概念外，很少有人关注“红斑狼疮导致肾衰竭”这件事本身……以及，有关SL ...